Last reviewed · How we verify
Haporine-S
Haporine-S is a small molecule that targets the PI3K/AKT/mTOR pathway.
Haporine-S is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic triple-negative breast cancer, Locally advanced or metastatic non-small cell lung cancer.
At a glance
| Generic name | Haporine-S |
|---|---|
| Sponsor | DH Bio Co., Ltd. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Haporine-S works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to reduced tumor growth and proliferation. Additionally, Haporine-S has been shown to induce apoptosis in cancer cells.
Approved indications
- Metastatic triple-negative breast cancer
- Locally advanced or metastatic non-small cell lung cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Haporine-S CI brief — competitive landscape report
- Haporine-S updates RSS · CI watch RSS
- DH Bio Co., Ltd. portfolio CI